ATRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Atara Biotherapeutics Inc (ATRA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant negative catalysts, poor financial performance, and lacks strong technical or proprietary trading signals to support a buy decision.
The stock is in a bearish trend with moving averages showing SMA_200 > SMA_20 > SMA_5. RSI is at 27.161, indicating a neutral zone with no clear signal. The MACD histogram is positive but contracting, suggesting weak momentum. The stock is trading near its support level of 4.463, with resistance levels at 5.399 and 5.688.
NULL identified. Analysts have raised price targets based on potential FDA approval of tab-cel in January 2026, but this is a long-term event and does not offset current negative sentiment.
The FDA issued a Complete Response Letter for EBVALLO™, leading to a 56.99% stock price drop. Pomerantz LLP is investigating potential securities fraud, creating further uncertainty. Hedge funds and insiders are heavily selling the stock. The company's financial performance has significantly deteriorated, with revenue, net income, and EPS all showing sharp declines.
In Q3 2025, revenue dropped by 91.41% YoY to $3.45M, net income fell by 80.36% YoY to -$4.3M, and EPS declined by 89.08% YoY to -$0.32. While gross margin increased to 96.67%, this is insufficient to offset the overall poor financial performance.
Analysts have raised price targets recently (Canaccord to $25 and Mizuho to $18) based on potential FDA approval of tab-cel in January 2026 and reduced operating expenses. However, these are long-term factors and do not address the immediate challenges facing the company.
